Background Recent data suggest that human epidermal growth factor receptor 2 (HER2)-low
breast cancer may represent a distinct entity. We aimed to compare disease characteristics …

Introduction The efficacy of immune checkpoint inhibitors (ICPi) in BRAF mutant NSCLC is
unknown. Methods Multi-institutional retrospective chart review identified 39 patients with …

Objectives Nivolumab has recently received regulatory approval as a 2nd-line treatment of
non-small cell lung cancer (NSCLC). The data regarding its effectiveness and safety in real …

Background Patients with lung cancer are at increased risk for venous thromboembolism (VTE),
particularly those receiving chemotherapy. It is estimated that 8% to 15% of patients with …

The DMFT index, which represents caries experience as recommended by the World Health
Organization (clinical examination without radiographs), was compared with a modified …

Objective: During the last decade, obesity has become an epidemic. As obesity is now
considered a state of low-grade inflammation, the purpose of this study was to assess the …

Background There are scarce data on venous thromboembolism (VTE) rates among non‐small
cell lung cancer (NSCLC) patients treated with immune‐checkpoint inhibitors (ICI). The …

This study was conducted to examine the relationship between the degree of asymptomatic
hyperuricemia and the development of gout, in men and women. The database of a …

Objectives Efficacy of immune check-point inhibitors (ICPi) in NSCLC with rare targetable
drivers (RTDs) is largely unknown. Materials and Methods Consecutive patients with NSCLC …

Objective To investigate the impact of late follicular phase progesterone (P) elevation in
relation to ovarian response on cycle outcome. Design Cohort study. The progesterone-to-…